DBV Technologies reported $49.48M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amarin USD 182.23M 3.71M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025